Comparative Pharmacology
Head-to-head clinical analysis: DELALUTIN versus ENDOMETRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELALUTIN versus ENDOMETRIN.
DELALUTIN vs ENDOMETRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progestogen; suppresses gonadotropin secretion, induces secretory endometrium, inhibits uterine contractions.
Progesterone is a steroid hormone that binds to progesterone receptors in the endometrium, inducing secretory changes, decreasing uterine contractility, and supporting pregnancy maintenance.
Hydroxyprogesterone caproate: 250-500 mg IM weekly, starting at 16-20 weeks gestation and continuing until 37 weeks or delivery, for prevention of preterm birth in women with singleton pregnancy and prior spontaneous preterm birth.
Vaginal tablet: 100 mg twice daily starting on day 15 of a 28-day cycle for 12 weeks.
None Documented
None Documented
Terminal elimination half-life approximately 5.5 days (range 3-7 days), supporting weekly intramuscular dosing for sustained progestational effect.
Terminal elimination half-life is approximately 12-15 hours, supporting twice-daily dosing for endometrial support.
Primarily renal; conjugated metabolites excreted in urine (50-60%) and bile/feces (30-40%).
Primarily renal (50-60% as metabolites, <10% unchanged); fecal (20-30%) via biliary excretion.
Category C
Category C
Progestin
Progestin